RxDoctor Payments DataLook up a doctor →

Mark Anderson, MD

Neurology · Jackson, MSNPI 1922202415

Payments from drug & device makers

$27,544in general payments, 2019–2025

Across 376 payments — averaging $73.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure GmbH$21K
  • Abiomed$571
  • Amgen$540
  • AbbVie$486
  • Johnson & Johnson$433
  • Novartis$342
  • plus $4K from 54 others

What the payments were for

  • Speaking & faculty fees$330%
  • Travel & lodging$3375%
  • Food & beverage$6,42395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novocure GmbH2$20,750
Abiomed6$571
Amgen(2 entities)33$540
AbbVie(2 entities)30$486
Johnson & Johnson(2 entities)34$433
Novartis17$342
Takeda Pharmaceuticals U.S.A., Inc.14$278
Acadia Pharmaceuticals Inc13$228
Pfizer13$226
Exelixis Inc.9$201
Incyte Corporation11$191
Sanofi9$164
Merck7$156
Sunovion Pharmaceuticals Inc.13$145
Biohaven Pharmaceutical Holding Company Ltd.6$108
AstraZeneca(2 entities)6$108
Karyopharm Therapeutics Inc.6$106
Emmaus Medical, Inc.6$106
Servier Pharmaceuticals LLC6$105
GSK6$96
Teva Pharmaceuticals USA, Inc.6$90
Beone Medicines USA, Inc.4$84
Astellas Pharma US Inc4$81
Rigel Pharmaceuticals, Inc.4$79
Tesaro, Inc.5$75
EMD Serono, Inc.5$75
Supernus Pharmaceuticals, Inc.6$73
Avanir Pharmaceuticals, Inc.5$72
Neurocrine Biosciences, Inc.4$66
Lilly USA, LLC5$65
Acorda Therapeutics, Inc4$65
Genentech USA, Inc.4$65
ADC Therapeutics America, Inc.3$63
Alnylam Pharmaceuticals Inc.4$61
Telix Pharmaceuticals1$60
Jazz Pharmaceuticals Inc.3$57
Seagen Inc.3$56
Pharmacosmos Therapeutics Inc.3$53
Eisai Inc.4$53
Novocure Inc.1$50
Kyowa Kirin, Inc.3$47
Bristol Myers Squibb2$45
Stemline Therapeutics Inc.2$45
Biohaven Pharmaceuticals, Inc.3$42
UCB, Inc.3$41
AVEO Pharmaceuticals, Inc.2$40
Secura Bio, Inc.3$37
Clovis Oncology, Inc.2$33
Taiho Oncology, Inc.1$32
Pharmaessentia USA Corporation2$31
Daiichi Sankyo Inc.1$29
Acceleron Pharma, Inc.2$28
Si-bone, Inc.1$24
Novo Nordisk1$23
Ipsen Biopharmaceuticals, Inc1$22
Lundbeck LLC1$21
Otsuka America Pharmaceutical, Inc.1$20
Puma Biotechnology, Inc.1$18
Epizyme, Inc.1$18
Agios Pharmaceuticals, Inc.1$18

How this compares

$27,544 in reported general payments places this provider in the 80th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$37,587
Medicare patients
218
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$145,844
AptiomEslicarbazepine Acetate21$41,498
UbrelvyUbrogepant34$40,320
Aimovig AutoinjectorErenumab-Aooe45$34,561
BriviactBrivaracetam18$32,828
Nurtec OdtRimegepant Sulfate16$26,511
Emgality PenGalcanezumab-Gnlm32$21,478
QuliptaAtogepant16$19,420
XcopriCenobamate13$15,091
Lacosamide96$13,232
Ajovy AutoinjectorFremanezumab-Vfrm18$12,565
Levetiracetam200$5,612
Mycophenolate Mofetil23$4,546
Pregabalin63$3,750
Oxcarbazepine45$3,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$486$59,74050 claims
Sunovion Pharmaceuticals Inc.Aptiom$145$41,49821 claims
UCB, Inc.Briviact$41$32,82818 claims
PfizerNurtec Odt$226$26,51116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 neurology providers in Mississippi.

Other neurology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →